Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Medical CoTSE:7775 -0.47%61 EV-to-EBIT is 9.97 as of Sep. 09, 2026, which is 29% below its 10-year median of 14.07. GuruFocus rates TSE:7775 with a GF Score™ of 61/100 and a GF Value™ of 円558.79 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 475 Medical Devices & Instruments companies, Daiken Medical Co ranks better than 74.95% on this metric.
The historical rank and industry rank for Daiken Medical Co's EV-to-EBIT or its related term are showing as below:
TSE:7775'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.85 Med: 14.07 Max: 20.19
Current: 9.96
During the past 13 years, the highest EV-to-EBIT of Daiken Medical Co was 20.19. The lowest was 8.85. And the median was 14.07.
TSE:7775's EV-to-EBIT is ranked better than 74.95% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 18.49
vs TSE:7775: 9.96
Daiken Medical Co (TSE:7775) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Daiken Medical Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円12,342 Mil.
Daiken Medical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,193 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Medical Co EV-to-EBIT Related Terms
Daiken Medical Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Daiken Medical Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Daiken Medical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Medical Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Daiken Medical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Daiken Medical Co's EV-to-EBIT falls into.
Daiken Medical Co's current Enterprise Value is 円11,886 Mil.
Daiken Medical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,193 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Medical Co (TSE:7775) has a EV-to-EBIT of 9.97 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daiken Medical Co and its competitors. This is 29% below median its historical median of 14.07. Over the past decade, Daiken Medical Co's EV-to-EBIT has ranged from 8.85 to 20.19. According to the industry distribution chart, Daiken Medical Co ranks #119 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 25.1%.
Is Daiken Medical Co's EV-to-EBIT too high?
Daiken Medical Co's current EV-to-EBIT of 9.97 is 29% below median its 10-year median of 14.07. Over the past 10 years, this metric has ranged from a low of 8.85 to a high of 20.19. The Medical Devices & Instruments industry median EV-to-EBIT is 18.49. Daiken Medical Co's value of 9.97 is 46.1% below this industry median. Based on the distribution chart, Daiken Medical Co ranks #119 out of 475 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Daiken Medical Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiken Medical Co's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Daiken Medical Co ranks #119 out of 475 companies for EV-to-EBIT. This puts Daiken Medical Co in the upper half of its industry. The industry median EV-to-EBIT is 18.49. Daiken Medical Co's value of 9.97 is 46.1% below this benchmark. Historically, Daiken Medical Co's own EV-to-EBIT has ranged from 8.85 to 20.19 over the past decade. While the company's 10-year median is 14.07 vs. the industry median of 18.49, Daiken Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.49, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Medical Co's current EV-to-EBIT of 9.97 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Daiken Medical Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Medical Co's current EV-to-EBIT is 9.97, which is 29% below median its own 10-year median of 14.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Daiken Medical Co (TSE:7775) is currently considered Modestly Undervalued. The stock's GF Value™ is 円558.79, compared to a current price of 円425.00 — trading 23.9% below its estimated fair value. The current EV-to-EBIT is 9.97, which is 29% below median its 10-year median of 14.07 and 46.1% below the Medical Devices & Instruments industry median of 18.49. Daiken Medical Co's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Daiken Medical Co (TSE:7775), the current EV-to-EBIT is 9.97 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiken Medical Co (TSE:7775) Overvalued in 2026?
Based on GuruFocus' analysis, Daiken Medical Co stock appears to be undervalued.
The current stock price of 円425.00 is trading 23.9% below its estimated GF Value™ of 円558.79.
GuruFocus considers Daiken Medical Co to be Modestly Undervalued.
Key valuation signals for TSE:7775:
EV-to-EBIT: 9.97 (29% below median its 10-year median of 14.07)
GF Value™: 円558.79 vs. price of 円425.00 (23.9% below fair value)
Industry Position: 46.1% below the Medical Devices & Instruments median (#119 of 475)
No single metric tells the full story. See the TSE:7775 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiken Medical Co Ltd manufactures and sells medical equipment. The product line includes - Coopdech syrinjector, Coopdech Syrinjector PCA device, Coopdech Balloonjector, Coopdech Endobronchial blocker tube, Coopdech double-lumen endobronchial tube, Fit fix suction container system, Wet disinfectant mat, and others.
61GF Score
Get the complete analysis for TSE:7775
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7775 has been successfully added to your 
